Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine)

Biochemical Pharmacology

Volumn 53, Issue 6, 1997, Pages 887-895

  Mahato, Ram I ^a   Takemura, Shigeo ^a   Akamatsu, Ken ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

hepatic uptake; macrophage; oligonucleotides; particle size; pharmacokinetics; zeta potential

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; POLYLYSINE;

ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ELECTROPHORESIS; GLYCOSYLATION; LIVER; MICE; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; POLYLYSINE; THIONUCLEOTIDES;

EID: 0030907837     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00880-5     Document Type: Article

References (40)

1. Crooke ST, Oligonucleotides as potential therapeutic agents. In: Trends and Future Perspectives in Peptides and Protein Drug Delivery (Eds. Lee VHL, Hashida M and Mizushima Y), pp. 297-320. Harwood Academic Publishers GmbH, Chur, Switzerland, 1995.
2. Mahato RI, Takakura Y and Hashida M, Development of targeted delivery systems for nucleic acid drugs. J Drug Target, in press, 1997.
3. Dean NM and McKay R, Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligonucleotides. Proc Natl Acad Sci USA 91: 11762-11766, 1994.
4. Agrawal S, Temsamani J and Tang JY, Pharmacokinetics, biodistribution, and stability of oligonucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599, 1991.
5. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267: 1181-1190, 1993.
6. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM and Agrawal S, Pharmacokinetics and tissue distribution in rats of an oligonucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49: 929-939, 1995.
7. Letsinger R, Zhang G, Sun DK, Ikeuchi T and Sarin PS, Cholesterol-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci USA 86: 6553-6556, 1989.
8. Akhtar S, Basu S, Wickstrom E and Juliano RL, Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res 19: 5551-5559, 1991.
9. 1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149: 13-19, 1994.
10. Leonetti JP, Degols G and Lebleu B, Biological activity of oligonucleotide poly(L-lysine) conjugates: Mechanism of cell uptake. Bioconjug Chem 1: 149-153, 1990.
11. Citro G, Perrotti D, Cucco C, D'Agnano I, Sacchi A, Zupi G and Calabretta B, Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxy-nucleotides. Proc Natl Acad Sci USA 89: 7031-7035, 1992.
12. Citro G, Szczylik C, Ginobbi P, Zupi G and Calabretta B, Inhibition of leukemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer 69: 463-467, 1994.
13. Wu GY and Wu CH, Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 267: 12436-12439, 1992.
14. Desphande D, Toledo-Velasquez D, Thakkar D, Liang WW and Rojanasakul Y, Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells. Pharm Res 13: 57-61 1996.
15. Bonfils E, Depierreux C, Midoux P, Thuong NT, Monsigny M and Roche AC, Drug targeting: Synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. Nucleic Acids Res 20: 4621-4629, 1992.
16. Liang WW, Shi X, Deshpande D, Malanga CJ, and Rojanasakul Y, Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim Biophys Acta 1279: 227-234, 1996.
17. Carmichael EP, Chiou HC, Findeis MA, Spitalny GL and Merwin JR, Targeted delivery of anti-hepatitis B antisense oligonucleotides. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics (Ed. Akhtar S), pp. 267-282. CRC Press, New York, 1995.
18. Ashwell G and Harford J, Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51: 531-554, 1982.
19. Desjardins J, Mata J, Brown T, Graham D, Zon G and Iversen P, Cholesteryl-conjugated phosphorothioate oligodeoxy-nucleotides modulate CYP2B1 expression in vivo. J Drug Target 2: 477-485, 1995.
20. Lee YC, Stowell CP and Kranz MJ, 2-Imino-2-methoxyethyl 1-thioglycosides: New reagents for attaching sugars to proteins. Biochemistry 15: 3956-3963, 1976.
21. Monsigny M, Petit C and Roche A-C, Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micro-method. Anal Biochem 175: 525-530, 1988.
22. Mahato RI, Kawabata K, Nomura T, Takakura Y and Hashida M, Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sci 84: 1267-1271, 1995.
23. Smoluchowski MV, Versuch einer mathematischen. Theorie der Koagulationekinetic kolloider Lösungen. Z Phys Chem 92: 129-168, 1918.
24. Mahato RI, Kawabata K, Takakura Y and Hashida M, In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 3: 149-157, 1995.
25. Nishikawa M, Ohtsubo Y, Ohno J, Fujita T, Koyama Y, Yamashita F, Hashida M and Sezaki H, Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. Int J Pharm 85: 75-85, 1992.
26. Bayever E, Iversen P, Smith L, Spinolo J and Zon Z, Systemic human antisense therapy begins. Antisense Res Dev 2: 109-110, 1992.
27. Miyao T, Takakura Y, Akiyama T, Yoneda F, Sezaki H and Hashida M, Stability and pharmacokinetics of oligonucleotides modified at terminal linkages in mice. Antisense Res Dev 5: 115-121, 1995.
28. Sawai K, Miyao T, Takakura Y and Hashida M, Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res Dev 5: 279-287, 1995.
29. Takakura Y, Mahato RI, Yoshida M, Kanamaru T and Hashida M, Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug Dev 6: 177-183, 1996.
30. Sawai K, Mahato RI, Oka Y, Takakura Y and Hashida M, Disposition of oligonucleotides in the isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 279: 284-290, 1996.
31. Takakura Y, Mahato RI and Hashida M, Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv Drug Delivery Rev 19: 377-400, 1996.
32. Mahato RI, Takakura Y and Hashida M, Nonviral vectors for in vivo gene delivery: Physicochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Syst 14: 85-124, 1997.
33. McBroom CR, Samanen CH and Goldstein IJ, Carbohydrate antigenes: Coupling of carbohydrates to proteins by diazonium and phenylisothiocyanate reactions. Methods Enzymol 28: 212-219, 1972.
34. Hnatowich DJ, Mardirossian G, Fogarasi M, Sano T, Smith CL, Cantor CR, Rusckowski M and Winnard P Jr, Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice. J Pharmacol Exp Ther 276: 326-334, 1996.
35. 3H]-labeled oligonucleotides. I. Comparison of phosphodiester and phosphorothioate. Mol Pharmacol 45: 932-943, 1994.
36. Inagaki M, Togawa K, Carr BI, Ghosh K and Cohen JS, Inhibition of liver cell proliferarion and in vivo disposition. Transplant Proc 24: 2971-2972, 1992.
37. 32P]-oligonucleotides on nonparenchymal liver cells. In: Cells of the Hepatic Sinusoid (Eds. Wisse E, Knock DL and Wake K), Vol. 5, pp. 358-361. Kupffer Cell Foundation, The Netherlands, 1995.
38. Schlepper-Schäffer J, Hülsmann D, Djovkar A, Meyer HE, Herbertz L, Kolb H and Kolb-Bachofen V, Endocytosis via galactose receptor in vivo: Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp Cell Res 165: 494-506, 1986.
39. Kuiper J, Bakkeren HF, Biessen EAL and Van Berkel TJC, Characterization of the interaction of galactose-exposing particles with rat Kupffer cells. Biochem J 299: 285-290, 1994.
40. Kawabata K, Takakura Y and Hashida M, The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake. Pharm Res 12: 825-830, 1995.